Wixela Inhub and Advair Diskus fluticasone-salmeterol are similarly effective and safe for COPD<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Aug. 7, 2023 (HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), generic and brand-name fluticasone-salmeterol are similarly effective and safe, according to a study published online Aug. 8 in the Annals of Internal Medicine<\/em>.<\/p>\n William B. Feldman, M.D., D.Phil., from Brigham and Women’s Hospital in Boston, and colleagues compared the effectiveness and safety of generic (Wixela Inhub) and brand-name (Advair Diskus) fluticasone-salmeterol among patients with COPD in a propensity score-matched cohort study. Of 27,305 Advair Diskus users and 18,064 Wixela Inhub users, 10,012 matched pairs were included in the primary analysis.<\/p>\n The researchers found that Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation compared with Advair Diskus (hazard ratio, 0.97; 95 percent confidence interval, 0.90 to 1.04) and with a similar incidence of first pneumonia hospitalization (hazard ratio, 0.99; 95 percent confidence interval, 0.86 to 1.15).<\/p>\n “In patients with COPD, the generic inhaled corticosteroid-long-acting \u00ce\u00b2-agonist Wixela Inhub had nearly identical effectiveness and safety when compared with brand-name Advair Diskus,” the authors write. “Similar studies can provide a useful means of evaluating the clinical effectiveness and safety of complex generic products after approval.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n